Search Clinical Trials
598,193 trials
ID
Status
Phase
Title
Sponsor
NCT07763288
Prevalence of Glaucoma and Normative Data of Ocular Biometry in Elderly Population in BangkokSiriraj HospitalCompleted
NCT07763288Completed
—
Prevalence of Glaucoma and Normative Data of Ocular Biometry in Elderly Populati...Siriraj Hospital
NCT07763626
Gdue Plus a Hypocaloric Mediterranean Diet in Adults With MASLDUniversity of GenovaCompletedNot Applicable
NCT07763626Completed
Not Applicable
Gdue Plus a Hypocaloric Mediterranean Diet in Adults With MASLDUniversity of Genova
NCT07762352
Ankle Brace vs Functional Taping In Adolescents With Chronic Ankle InstabilityEscola Superior de Saude do AlcoitaoCompletedNot Applicable
NCT07762352Completed
Not Applicable
Ankle Brace vs Functional Taping In Adolescents With Chronic Ankle InstabilityEscola Superior de Saude...
NCT07764133
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation and a Predictor of Treatment Response in Ovarian CancerUniversity of Tennessee Graduate School of MedicineRecruiting
NCT07764133Recruiting
—
Whole Body Metabolic Activity as a Reflection of Tumor Metabolic Dysregulation a...University of Tennessee G...
NCT07764224
Cold Versus Hot Snare Endoscopic Mucosal Resection for Intermediate-Size Flat Nonpedunculated Colorectal PolypsAnyuan County People's Hospital of GanzhouNot Yet RecruitingNot Applicable
NCT07764224Not Yet Recruiting
Not Applicable
Cold Versus Hot Snare Endoscopic Mucosal Resection for Intermediate-Size Flat No...Anyuan County People's Ho...
NCT07763938
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell MalignanciesNanjing Legend Biotech Co.Not Yet RecruitingPhase 1
NCT07763938Not Yet Recruiting
Phase 1
CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relap...Nanjing Legend Biotech Co...
NCT07762261
Impact of Generative AI on University Students' Learning Processes and Critical ThinkingAtaturk UniversityNot Yet RecruitingNot Applicable
NCT07762261Not Yet Recruiting
Not Applicable
Impact of Generative AI on University Students' Learning Processes and Critical...Ataturk University
NCT07763132
Comparison of Virtual Reality, EMLA Cream, and Standard Care for Pain During Blood Draws in ChildrenMarie LulkováRecruitingNot Applicable
NCT07763132Recruiting
Not Applicable
Comparison of Virtual Reality, EMLA Cream, and Standard Care for Pain During Blo...Marie Lulková
NCT07763262
Autologous Nanofat Injection for Treatment of Stable VitiligoBenha UniversityCompletedNot Applicable
NCT07763262Completed
Not Applicable
Autologous Nanofat Injection for Treatment of Stable VitiligoBenha University
NCT07762547
Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.Beijing Tiantan HospitalNot Yet RecruitingNot Applicable
NCT07762547Not Yet Recruiting
Not Applicable
Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moy...Beijing Tiantan Hospital
NCT07762625
Couple-Coordinated Lifestyle Intervention for Women With a History of Gestational Diabetes MellitusCentral South UniversityNot Yet RecruitingNot Applicable
NCT07762625Not Yet Recruiting
Not Applicable
Couple-Coordinated Lifestyle Intervention for Women With a History of Gestationa...Central South University
NCT07761962
Laser Assisted Pulpotomy Versus MTA Pulpotomy in Permanent Teeth With Irreversible PulpitisKing Abdullah University HospitalActive Not RecruitingNot Applicable
NCT07761962Active Not Recruiting
Not Applicable
Laser Assisted Pulpotomy Versus MTA Pulpotomy in Permanent Teeth With Irreversib...King Abdullah University...
NCT07764107
Photobiomodulation for Reducing Sedative-Hypnotic Use:Clinical Trial of a Light-Therapy DeviceNational Health Research Institutes, TaiwanNot Yet RecruitingNot Applicable
NCT07764107Not Yet Recruiting
Not Applicable
Photobiomodulation for Reducing Sedative-Hypnotic Use:Clinical Trial of a Light-...National Health Research...
NCT07762001
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MDActive Not RecruitingPhase 1
NCT07762001Active Not Recruiting
Phase 1
Phase 1 Single-blind Placebo-controlled Dose Escalation Safety Study of AD-NP1Arjun Deb, MD
NCT07762911
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)University Hospital, Basel, SwitzerlandRecruitingNot Applicable
NCT07762911Recruiting
Not Applicable
Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year...University Hospital, Base...
NCT07762131
AI-Based Precision Transfusion Prediction Model in Critically Ill PatientsSecond Affiliated Hospital, Zhejiang University, School of MedicineNot Yet Recruiting
NCT07762131Not Yet Recruiting
—
AI-Based Precision Transfusion Prediction Model in Critically Ill PatientsSecond Affiliated Hospita...
NCT07763418
A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participants With Severe Renal Impairment and End-Stage Renal Disease Compared With Participants With Normal Renal FunctionBristol-Myers SquibbNot Yet RecruitingPhase 1
NCT07763418Not Yet Recruiting
Phase 1
A Study to Evaluate the Pharmacokinetics and Safety of Golcadomide in Participan...Bristol-Myers Squibb
NCT07763093
Vertically Coronally Advanced Flap Versus Coronally Advanced Flap for Miller Class I Gingival RecessionUniversity of Medicine and Pharmacy at Ho Chi Minh CityActive Not RecruitingNot Applicable
NCT07763093Active Not Recruiting
Not Applicable
Vertically Coronally Advanced Flap Versus Coronally Advanced Flap for Miller Cla...University of Medicine an...
NCT07762443
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia AreataJiangsu vcare pharmaceutical technology co., LTDNot Yet RecruitingPhase 1
NCT07762443Not Yet Recruiting
Phase 1
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Are...Jiangsu vcare pharmaceuti...
Result Breakdown
Not yet recruiting9 (45%)
Completed5 (25%)
Recruiting3 (15%)
Active, not recruiting3 (15%)
not_applicable13 (65%)
Phase 14 (20%)
Not Specified3 (15%)